SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, superior bystander killing effect and favorable safety profiles

药代动力学 药理学 旁观者效应 抗体-药物偶联物 细胞毒性 药品 曲妥珠单抗 毒性 抗体 治疗指标 医学 化学 单克隆抗体 癌症 免疫学 体外 内科学 乳腺癌 生物化学
作者
Ting Zhang,Jianyan Xu,Junzhao Yin,Yun Gao,Han–Wen Zheng,Beibei Fu,Jiakang Sun,Zhibing Xu,Shiwei Tu,Yuchang Mao,Weiyun Wen,Bolei Qu,Lingfeng You,Zhendong Xue,Xing Sun,Dan Cao,Jun Feng,Min Hu,Feng He
出处
期刊:Research Square - Research Square [Research Square (United States)]
被引量:2
标识
DOI:10.21203/rs.3.rs-3770094/v1
摘要

Abstract Background HER2-targeting antibody–drug conjugates (ADCs), especially trastuzumab deruxtecan (T-DXd), have revolutionized the treatment landscape of HER2-expressing or mutant cancers. However, undesired adverse events are still inevitable. It is necessary to discover a novel HER2-directed ADC with better safety profiles. Methods SHR-A1811 is composed of trastuzumab, a cleavable linker and a novel topoisomerase I inhibitor, SHR169265. The permeability and pharmacokinetics of SHR169265 were detected by PAMPA assay and LC-MS/MS System. CellTiter-Glo cell viability assay was used to determine the cytotoxicity and bystander killing effect of SHR169265 and SHR-A1811. The antitumor efficacy of SHR-A1811 was evaluated in mouse xenograft models with different HER2 expression levels. The toxicity of SHR-A1811 were evaluated in cynomolgus monkeys. Results SHR169265 showed better permeability, stronger cytotoxicity and faster systemic clearance than SHR197971 (a DXd analog). The drug-to-antibody ratio (DAR) of SHR-A1811 was optimized as 6 via balancing efficacy and toxicity. SHR-A1811 showed HER2-dependent growth inhibition against various cell lines and desirable bystander killing capability. SHR-A1811 led to tumor growth inhibition or even regression in a dose-dependent manner, at least comparable as HRA18-C015 (a biosimilar of T-DXd) and anti-HER2-SHR169265 (DAR 8) in multiple xenograft models with a range of HER2 expression levels. SHR-A1811 exhibited a good pharmacokinetics profile, outstanding stability in plasma across different species and a favorable preclinical safety profile. The highest non-severely toxic dose (HNSTD) in cynomolgus monkeys was 40 mg/kg with thymus as the main target organ. Conclusions SHR-A1811 is a potential best-in-class anti-HER2 ADC with a highly permeable payload, optimized DAR, great potency and better safety profiles. Currently SHR-A1811 has entered phase II and phase III clinical studies for breast cancer, gastric cancer, colorectal cancer, and NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王梦瑶完成签到 ,获得积分10
刚刚
1秒前
谢尔顿发布了新的文献求助10
1秒前
林林关注了科研通微信公众号
1秒前
FashionBoy的应助被苑小胖采纳,获得10
1秒前
1秒前
高大抽屉完成签到,获得积分10
2秒前
2秒前
3秒前
馒头发布了新的文献求助10
3秒前
17826539164关注了科研通微信公众号
4秒前
4秒前
无极微光的应助被科研通管家采纳,获得20
5秒前
Jun的应助被科研通管家采纳,获得10
5秒前
SciGPT的应助被科研通管家采纳,获得10
5秒前
Jun的应助被科研通管家采纳,获得10
5秒前
天天快乐的应助被科研通管家采纳,获得10
5秒前
Jasper的应助被科研通管家采纳,获得10
5秒前
传奇3的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得20
5秒前
6秒前
Owen的应助被科研通管家采纳,获得10
6秒前
初景的应助被科研通管家采纳,获得20
6秒前
李爱国的应助被科研通管家采纳,获得10
6秒前
原味薯片完成签到,获得积分10
6秒前
深情安青的应助被科研通管家采纳,获得10
6秒前
余香的应助被科研通管家采纳,获得10
6秒前
秋风的应助被科研通管家采纳,获得20
6秒前
小二郎的应助被科研通管家采纳,获得10
7秒前
在水一方的应助被科研通管家采纳,获得10
7秒前
7秒前
传奇3的应助被科研通管家采纳,获得10
7秒前
大河同志发布了新的文献求助10
7秒前
7秒前
7秒前
君无双的应助被科研通管家采纳,获得10
7秒前
爆米花的应助被科研通管家采纳,获得10
7秒前
思源的应助被科研通管家采纳,获得10
7秒前
7秒前
酷波er的应助被科研通管家采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187612
求助须知:如何正确求助?哪些是违规求助? 9575734
关于积分的说明 21842594
捐赠科研通 7785476
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559478
邀请新用户注册赠送积分活动 2481952